Abstract:BACKGROUND & OBJECTIVE:ZD1839, an anilinoquinazoline, is an orally active, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which has been approved for the treatment of advanced non-small cell lung cancer by FDA. Nasopharyngeal carcinoma is of epithelial origin with overexpression of epidermal growth factor receptor and it remains unclear whether ZD1839 is useful in the treatment of nasopharyngeal carcinoma. The present study was designed to evaluate the effect of ZD1839 on nasopharyngeal carcinoma cell lines.METHODS:The effect of ZD1839 on nasopharyngeal carcinoma cells (CNE1, CNE2, SUNE1) was determined by MTT assay. The effect of ZD1839 combined with cisplatin (DDP) or 5-fluouracil (5-FU) on nasopharyngeal carcinoma cell CNE2 was also evaluated. Burgi formula was adopted to analyze combination effect. The distribution of cell cycle and cell apoptosis rate were analyzed by flow cytometry.RESULTS:The proliferation of nasopharyngeal carcinoma cell lines CNE1, CNE2, and SUNE1 was inhibited by ZD1839, and the effect was dose-dependent. The value of IC50 for the effect of ZD1839 on nasopharyngeal carcinoma cell lines CNE1, CNE2, and SUNE1 was 3.9 micromol/L, 5.6 micromol/L, and 5.5 micromol/L, respectively. ZD1839 could enhance the effect of DDP and 5-FU on CNE2 cells. The Q values by Burgi formula were 1.19+/-0.02 and 1.12+/-0.10, respectively. When CNE2 cells were treated with ZD1839 at the concentration of 0, 1.95, 3.9, 7.8, 15.6, 31.25 micromol/L, the percentages of G(0)/G(1) phase were (46.8+/-1.7)%, (48.8+/-1.6)%, (51.3+/-1.3)%, (54.0+/-1.3)%, (61.5+/-2.2)%, and (71.2+/-1.4)%, respectively; the percentages of S phase were (37.5+/-1.3)%, (35.8+/-1.6)%, (31.8+/-2.1)%, (34.3+/-2.7)%, (27.2+/-2.9)%, and (27.6+/-2.4)%, respectively;the percentages of G(2)/M phase were (15.7+/-0.4)%, (15.3+/-0.1)%, (16.9+/-0.9)%, (11.7+/-1.4)%, (11.3+/-0.7)%, and (1.1+/-0.8)%, respectively. When CNE2 cells were treated with ZD1839 at the concentration of 0, 1.95, 3.9, 7.8, 15.6, 31.25, 62.5 micromol/L, the rates of CNE2 cell apoptosis were (1.6+/-0.3)%, (1.7+/-0.3)%, (2.3+/-0.4)%, (3.3+/-0.4)%, (3.9+/-0.8)%,(8.0+/-1.1)%,and(14.3+/-2.3)%, respectively.CONCLUSION:ZD1839 inhibits the proliferation of nasopharyngeal carcinoma cells and enhances the effect of cytotoxic drugs.ZD1839 induces CNE2 cell cycle arrest in the G1 phase and higher concentration of ZD1839 could induce apoptosis.

[AZD9291 suppresses proliferation and migration of nasopharyngeal carcinoma cells by inhibiting the PI3K-AKT-mTOR pathway]

A Low Dose of AZD8055 Enhances Radiosensitivity of Nasopharyngeal Carcinoma Cells by Activating Autophagy and Apoptosis

AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells.

[Effect of Epidermal Growth Factor Receptor-Selective Tyrosine Kinase Inhibitor ZD1839 on Nasopharyngeal Carcinoma Cells].

Induction of Cell Cycle Arrest and Apoptosis in Human Nasopharyngeal Carcinoma Cells by ZD6474, an Inhibitor of VEGFR Tyrosine Kinase with Additional Activity Against EGFR Tyrosine Kinase

Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro.

EGFR Tyrosine Kinase Inhibitor AG1478 Inhibits Cell Proliferation and Arrests Cell Cycle in Nasopharyngeal Carcinoma Cells

ZD1839 and cisplatin alone or in combination for treatment of a nasopharyngeal carcinoma cell line and Xenografts.

The anticancer effect of EGFR-targeting artificial microRNA controlled by SLPI promoter in nasopharyngeal carcinoma

Mtor Inhibitor AZD8055 Inhibits Proliferation and Induces Apoptosis in Laryngeal Carcinoma.

Targeting the JAK1 /STAT3 Signaling Pathway: Entinostat as a Promising Treatment for Nasopharyngeal Carcinoma

AZD9291 Increases Sensitivity to Radiation in PC-9-IR Cells by Delaying DNA Damage Repair after Irradiation and Inducing Apoptosis.

Abstract 3951: Dual phosphoinositide 3-kinase/Mammalian target of rapamycin inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma

Downregulation of Lncrna CCHE1 Inhibits Cell Proliferation, Migration and Invasion by Suppressing MEK/ERK/c-MYC Pathway in Nasopharyngeal Carcinoma.

Effects of Arctigenin in Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma 5-8F Cells

AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells

ARHGAP42 Promotes Cell Migration and Invasion Involving PI3K/Akt Signaling Pathway in Nasopharyngeal Carcinoma

Resveratrol Inhibits Nasopharyngeal Carcinoma (NPC) by Targeting the MAPK Signaling Pathway

[Pristimerin enhances cisplatin-induced apoptosis in nasopharyngeal carcinoma cells via ROS-mediated deactivation of the PI3K/AKT signaling pathway]

[Effects of Enhancer of Zeste Homolog (EZH2) Downregulation on the Proliferation and Invasion of Nasopharyngeal Carcinoma Cell and the Possible Mechanisms].

Abstract 4103: Knockdown of Notch1 Inhibits Tumor Cell Proliferation, Migration, and Invasion and Reverses Epithelial-Mesenchymal Transition (EMT) in Nasopharyngeal Carcinoma